Evolution of capecitabine dosing in breast cancer

Clinical Breast Cancer

Volumn 10, Issue 2, 2010, Pages 130-135

  Naughton, Michael ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Docetaxel; Metastatic breast cancer; Tolerability

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ETHNICITY; FATIGUE; FEBRILE NEUTROPENIA; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PROTEINURIA; REVIEW; RISK ASSESSMENT; STOMATITIS; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77950471223     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.017     Document Type: Review

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493 (Pubitemid 29075232)
3. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768 (Pubitemid 32952493)
4. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823 (Pubitemid 34651510)
5. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118-2123
6. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28:619-626
7. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2:93-109.
8. Pacanowski MA, Gong Y, Cooper-Dehoff RM, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84:715-721
9. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44:1209-1225 (Pubitemid 41832564)
10. Reigner B, Watanabe T, Schüller J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003; 52:193-201. (Pubitemid 37204532)
11. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000; 19:A400.
12. Leonard R, O'Shaughnessy J, Vukelja S, et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17:1379-1385 (Pubitemid 44400375)
13. Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16:1289-1296
14. Stockler M, Sourjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007; 25(suppl):A1031.
15. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23:2155-2161 (Pubitemid 46218707)
16. El Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005; 14:368-374
17. Yap YS, Kendall A, Walsh G, et al. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer-how low can you go? Breast 2007; 16:420-424 (Pubitemid 47109200)
18. Sezgin C, Kurt E, Evrensel T, et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007; 100:27-32. (Pubitemid 46104929)
19. Mavroudis D, Papakotoulas P, Ardavanis A, et al. Docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with advanced breast cancer. Final results of a multicenter phase III trial. Presented at: European Society of Medical Oncology; September 12-16, 2008; Stockholm, Sweden. Abstract 1360.
20. Luporsi E, Bachelot T, Bajard A, et al Comparative efficacy of first-line docetaxel + capecitabine (XT) versus docetaxel + epirubicin (ET): Pooled analysis of two randomised trials. Presented at: European Society of Medical Oncology; September 12-16, 2008; Stockholm, Sweden. Abstract 149P.
21. Lük H-J, DuBois A, Schrader I, et al. Final results of the AGO breast cancer study group MAMMA-3 trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for high-risk metastatic breast cancer. Breast Cancer Res Treat 2007; 106(suppl 1):S67 (abstract 1076).
22. Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006; 24(suppl):A570.
23. Yanagisawa M, F-Ouchi K, Tanaka Y. Optimal dosing schedule of capecitabine administration in human mammary tumor xenograft models. Presented at: 95th American Association for Cancer Research Annual Meeting; March 27-31, 2004; Orlando, Florida. Abstract 3086.
24. Lokich J. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest 2004; 22:713-717 (Pubitemid 40064731)
25. Martin M, Casado, GarciaSaenz JA, et al. Phase II randomized study of capecitabine (C) administered as continuous versus standard (cyclic) treatment in patients (pts) with metastatic breast cancer (MBC). Ann Oncol 2006; 17(suppl 9):158P.
26. Watanabe T, Katsumata N, Sasaki Y, et al. A multicenter phase II trial of Xeloda (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:A1991.
27. Kusama M, Sano M, Ikeda T, et al. A phase II study of Xeloda (capecitabine) in patients with advanced/metastatic breast carcinoma: The Cooperative Study Group of Capecitabine for Breast Cancer. Proc Am Soc Clin Oncol 2001; 20:A1924.
28. Saeki T, Kimura T, Toi M, et al. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer 2006; 13:49-57.
29. Osako T, Ito Y, Takahashi S, et al. Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori 2007; 93:129-132 (Pubitemid 46866701)
30. Taguchi T, Nakayama T, Masuda N, et al. Low-dose capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC): KBCSG 0408. Presented at: ASCO 2008 Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 193.
31. Puglisi F, Cardellino GG, Crivellari D, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxelmodulated capecitabine for metastatic breast cancer. Ann Oncol 2008; 19:1541-1546
32. Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/ gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 2009; 63:851-857
33. Krishnamurthi SS, Brell JM, Hoppel CL, et al. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol 2009; 63:441-450
34. Ugidos L, Delgado S, Conill C, et al. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. Invest New Drugs 2009; 27:262-268
35. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002; 2:267-310. (Pubitemid 34649876)
36. Levy E, Pierga J, Largillier R, et al. Randomized study evaluating an alternative schedule of capecitabine (X) as monotherapy for metastatic breast cancer (MBC): safety and pharmacokinetic results. Presented at: ASCO 2008 Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 188.
37. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-1097 (Pubitemid 28167730)
38. Pentheroudakis G, Pappas P, Golfinopoulos V, et al. Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol 2007; 60:733-739 (Pubitemid 47247284)
39. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10:370-381 (Pubitemid 40993565)
40. Norton L, Dugan U, Young D, et al. Optimizing chemotherapeutic dose-schedule (CDS) by Norton-Simon Modeling: Capecitabine (Xeloda=X). Presented at: 96th American Association for Cancer Research Annual Meeting; April 16-20, 2005; Anaheim, California. Abstract 5007.
41. Traina TA, Theodoulou M, Higgins B, et al. In vivo activity of a novel regimen of capecitabine (C) in a breast cancer xenograft model. Breast Cancer Res Treat 2006; 100(suppl 1):S279-80 (abstract 6071).
42. Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008; 26:1797-1802
43. Traina TA, Theodoulou M, Dugan U, et al. A novel capecitabine doising schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer. A phase II study. Cancer Res 2009; 69(suppl):395s (abstract 6121).
44. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43:1011-1016
45. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006; 12:5496-5502 (Pubitemid 44497266)